Showing 2841-2850 of 3315 results for "".
- HK Scientist Develops Retinal Scan Technology to Identify Early Childhood Autismhttps://modernod.com/news/hk-scientist-develops-retinal-scan-technology-to-identify-early-childhood-autism/2478987/A Hong Kong scientist has developed a method to use machine learning and artificial intelligence to scan retinas of children as young as six to detect early autism or the risk of autism and hopes to develop a commercial product this year, according to a Reuters
- CorneaGen Names Bernie Iliakis Presidenthttps://modernod.com/news/corneagen-names-bernie-iliakis-president/2478979/CorneaGen announced that Bernardino “Bernie” Iliakis has been promoted from chief operating officer to president of the company. Mr. Iliakis will assume leadership of the company as part of Monty Montoya’s transition from CEO to strategic advisor to CorneaGen.
- Kala Pharmaceuticals Announces Preferred Position for Eysuvis on Cignahttps://modernod.com/news/kala-pharmaceuticals-announces-preferred-position-for-eysuvis-on-cigna/2478977/Kala Pharmaceuticals announced that Cigna has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a preferred brand on its commercial formulary, effective May 15, 2021. “We are pleased to announce the addition of Eysuvis to Cigna’s preferred formulary, reflecting a signifi
- Newly Formed Ophthalmology Foundation Will Improve Global Eye Care Through Educationhttps://modernod.com/news/newly-formed-ophthalmology-foundation-will-improve-global-eye-care-through-education/2478972/The newly incorporated nonprofit Ophthalmology Foundation is laying the groundwork to improve global eye care and ophthalmic practice, particularly in low-resource and underserved countries, according to a company news release. Led by a global board of ophthalmologists, ophthalmology professors,
- Visus Therapeutics Announces FDA Acceptance of IND to Proceed With Clinical Development of Presbyopia-Correcting Eye Drophttps://modernod.com/news/visus-therapeutics-announces-fda-acceptance-of-ind-for-presbyopia-correcting-eye-drop/2478973/Visus Therapeutics announced that the FDA has accepted the company’s investigational new drug application (IND) to proceed with the clinical development program for Brimochol, the company’s lead investigational asset. Under this IND, Visus will initiate its planned phase 2 clinical trial in the U
- Johnson & Johnson Vision Introduces Acuvue Oasys Multifocal with Pupil Optimized Designhttps://modernod.com/news/johnson-johnson-vision-introduces-acuvue-oasys-multifocal-with-pupil-optimized-design/2478970/Johnson & Johnson Vision has introduced a new eye care option for patients with presbyopia: Acuvue Oasys Multifocal Contact Lenses with Pupil Optimized Design. The new lens is now available in the United States and Canada.
- Visus Therapeutics Announces $36 Million Series A Financing to Advance Development of Novel Presbyopia-Correcting Eye Drophttps://modernod.com/news/visus-therapeutics-announces-36-million-series-a-financing-to-advance-development-of-novel-presbyopia-correcting-eye-drop/2478952/Visus Therapeutics announced the close of a $36 million Series A Preferred Stock financing to advance the clinical development program for the company’s lead asset, Brimochol, an investigational drug designed to be a
- CorNeat Vision Partners with LiveU and Alcon for Remote Surgeon Virtual Presencehttps://modernod.com/news/corneat-vision-partners-with-liveu-and-alcon-for-remote-surgeon-virtual-presence/2478949/CorNeat Vision and LiveU, a provider of live video streaming and remote production solutions, announced that they have partnered and implemented an on-demand Remote Surgeon Virtual Presence (RSVP) solution. The companies cooperated with Alcon to leverage its NGENUITY 3D Visualization Syste
- Researchers Develop New Noninvasive Technique to Image Human Eyehttps://modernod.com/news/researchers-develop-new-noninvasive-technique-to-image-human-eye/2478947/Researchers have developed a noninvasive technique that can capture images of rod and cone photoreceptors with unprecedented detail. The advance could lead to new treatments and earlier detection for retinal diseases such as macular degeneration, according to a National Eye Institute news release
- Retinal Therapeutics Development Company Oxular Completes $37 Million (£27 million) Financinghttps://modernod.com/news/retinal-therapeutics-development-company-oxular-completes-37-million-27-million-financing/2478922/Oxular announced that it has completed a $37 million (£27 million) to fund planned further clinical development of its lead asset, OXU-001, for the treatment of diabetic macular edema (DME), as well as accelerating development of its early-product pipeline. The financing was led by Forbion